CymaBay Therapeutics

$7.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.36 (-4.63%) Today
$0.00 (0.00%) As of 6:11 AM EST after-hours

Why Robinhood?

You can buy or sell CBAY and other stocks, options, and ETFs commission-free!

About CBAY

CymaBay Therapeutics Inc. Common Stock, also called CymaBay Therapeutics, is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. The listed name for CBAY is CymaBay Therapeutics Inc. Common Stock.

CEO
Sujal Shah
Employees
60
Headquarters
Newark, California
Founded
1988
Market Cap
510.45M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.06M
High Today
$7.82
Low Today
$7.30
Open Price
$7.78
Volume
1.22M
52 Week High
$9.06
52 Week Low
$1.21

Collections

CBAY Earnings

-$0.43
-$0.29
-$0.14
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, After Hours

You May Also Like